Vaccinium macrocarpon extract and its anti-aging cosmetic effects

Abstract

The present invention relates to an extract of Vaccinium macrocarpon comprising at least 80% peptides by weight of dry matter of the extract, in particular a cosmetic active ingredient comprising it, a cosmetic composition comprising said active ingredient and anti-aging cosmetic uses.

Description

Title of the invention: Vaccinium macrocarpon extract and its anti-aging cosmetic effects Technical field

[0001] The invention relates to an extract of Vaccinium macrocarpon comprising at least 80% of peptides by weight of dry matter of the extract, in particular a cosmetic active ingredient comprising it, a cosmetic composition comprising said active ingredient and its anti-aging cosmetic uses.

[0002] State of the art

[0003] The rise of videoconferencing has profoundly changed our personal and professional communication methods and has created new cosmetic concerns, such as Zoom face. This phenomenon occurs when our face appears live and in close-up on the screen and we can't help but analyze the wrinkles and other defects that come to life along with our expressions. Thus, the boom in virtual meetings has led to a boom in internet searches for comprehensive anti-aging solutions.

[0004] The range of anti-aging ingredients is plentiful. Many active molecules are already known for their cosmetic effectiveness and safety. Among these so-called reference molecules, we can cite retinol, niacinamide, vitamins C and E, and peptides. These have established themselves as essential ingredients since the 1980s, when they began to be incorporated into cosmetic products.

[0005] Most peptides on the market are of synthetic origin, derived from the chemical or biotechnology industry. Synthetic peptides are certainly powerful in their effectiveness, but have the disadvantage of being restricted to a biological target. Although they are described as natural due to their amino acid composition, their chemical production requires the use of toxic solvents. Synthesis by biotechnology, on the other hand, requires the use of genetically modified organisms (GMOs). These manufacturing methods are no longer in line with the current needs of consumers who place cosmetic care products from the botanical world at the top of their expectations.

[0006] However, the plant world contains a great diversity of molecules among which natural peptides stand out as very promising active compounds. Although some peptides exist freely in this form, most are derived from native proteins from which they can be released by hydrolysis.

[0007] There is therefore a need for new cosmetic ingredients of natural and made up of peptides of natural origin to fight against skin aging and thus presenting an overall anti-aging effectiveness. Summary of the invention

[0008] To meet this need, the invention proposes a new extract obtained from cranberry (Vaccinium macrocarpon) comprising at least 80% of peptides by weight of dry matter of the extract, in particular it is a cosmetic active ingredient comprising said extract for an anti-aging cosmetic application.

[0009] Cranberry (Vaccinium macrocarpon (A.)) is an evergreen shrub measuring about thirty centimeters. It grows wild in the acidic peat bogs of cold regions, mountain forests and sandy meadows of North America. When summer comes, pink and purple bell-shaped flowers offer their open corollas to pollinators. As the season progresses, the development of red berries transforms these regions into vast flamboyant expanses. It is in autumn that the ripe fruits are harvested.

[0010] Cranberry, also called Atoca by Native Americans, was traditionally used for its medicinal properties. When the first Europeans arrived in the United States, the settlers in turn discovered and appreciated this tangy-tasting berry. From the middle of the 19th century, German doctors helped to spread its consumption in the modern world. Cranberry gradually became the health food of our time and is considered today a true superfruit.

[0011] Cranberries are particularly well known for their nutritional and health benefits, particularly their antioxidant effects. Cranberries are rich in vitamin C and other antioxidants that help prevent the onset of certain cancers, cardiovascular diseases, and various diseases related to aging. Cranberries are also used to prevent urinary tract infections, as well as to treat or prevent gingivitis and periodontitis.

[0012] Finally, anti-aging virtues have been attributed to it due to the presence of numerous anti-oxidant molecules.

[0013] The present invention relates to a specific extract rich in peptides and devoid of the antioxidant molecules naturally present in the fruit, and having cosmetic efficacy, in particular anti-aging.

[0014] Thus, the invention relates to an extract of Vaccinium macrocarpon comprising at least 80% of peptides by weight of dry matter of the extract.

[0015] Preferably, said extract is obtained from the fruits of Vaccinium macrocarpon, more preferably from the cakes of Vaccinium macrocarpon.

[0016] Said extract is a cosmetic active ingredient of particular interest as a natural ingredient for combating skin aging.

[0017] Thus, the cosmetic active ingredient according to the invention comprising the peptides of natural origin advantageously has an overall anti-aging effect, in particular it has an anti-wrinkle effect and / or makes it possible to improve the radiance of the complexion and / or to improve the quality of the dermo-epidermal junction, and / or to improve cutaneous homeostasis.

[0018] It therefore responds to the problems of the prior art and the present invention aims at the cosmetic applications cited above, preferably when the active ingredient is integrated into a cosmetic composition comprising at least 0.1% of said active ingredient and a physiologically acceptable medium, for topical application.

[0019] The present invention also relates to a process for obtaining the active ingredient according to the invention comprising in particular solubilization of Vaccinium macrocarpon fruit cakes in water, followed by enzymatic hydrolysis, separation of the soluble and insoluble phase and recovery of the soluble phase, enzymatic inactivation, purification of the peptide fraction and optionally concentration of the extract followed by sterilizing filtration.

[0020] Other characteristics and advantages will emerge from the detailed description of the invention and the examples which follow. Detailed description of the invention

[0021] Definition

[0022] By "cosmetic active ingredient" within the meaning of the invention, we mean an extract comprising at least one molecule, preferably a set of molecules, more preferably the molecules are peptides, having a cosmetic effect on the skin. Preferably the cosmetic effect on the skin is an anti-aging effect.

[0023] For the purposes of the invention, the term “Vaccinium macrocarpon” means a shrub of the Ericaceae family, also known as Cranberry, Cranberry (in English) or under the scientific names: Oxycoca macrocarpa (A.), Oxycoccus macrocarpus (A.) or Schollera macrocarpos (A.)■

[0024] By "hydrolysate of "Vaccinium macrocarpon" within the meaning of the invention, is meant any active ingredient derived from the fruits of Vaccinium macrocarpon, in particular from the cakes of Vaccinium macrocarpon, obtained by a process comprising at least one hydrolysis step, preferably two successive hydrolysis steps of Vaccinium macrocarpon. The term hydrolysate of Vaccinium macrocarpon excludes molecules extracted solely by maceration or decantation of Vaccinium macrocarpon.

[0025] For the purposes of the invention, the term “peptides” means peptides of size, expressed in molar mass, less than or equal to 2,000 Da.

[0026] For the purposes of the invention, the term “acidic amino acids” means a negatively charged amino acid at neutral pH, such as aspartic acid or glutamic acid.

[0027] For the purposes of the invention, the term “basic amino acids” means a positively charged amino acid at neutral pH, such as arginine, histidine or lysine.

[0028] By "cationic peptides" within the meaning of the invention, we mean peptides of size, expressed in molar mass, less than or equal to 2,000 Da and formed mainly of basic amino acids.

[0029] For the purposes of the invention, the term "cake" means the solid residues resulting from the extraction of oil from seeds or fruits, in particular from the seeds and pulp of Vaccinium macrocarpon. The seeds and pulp are in particular crushed and the oil is extracted by a cold-pressing extraction process well known to those skilled in the art. This process makes it possible to recover the cranberry oil and the solid residual co-products: the cakes.

[0030] For the purposes of the invention, the term "film" means a cosmetic product that is applied momentarily to the skin and removed after a certain application time, having a cosmetic or dermocosmetic effect. It may, for example, be a mask, a patch or a strip, for the face or the body.

[0031] Active ingredient according to the invention

[0032] The subject of the present invention is therefore a cosmetic active ingredient comprising at least one extract of Vaccinium macrocarpon comprising at least 80% of peptides by weight of dry matter of the extract.

[0033] The extract according to the invention is an ingredient of natural origin, including the peptides present in said extract. The specificity of the extract according to the invention is that it is made up of at least 80% of peptides of natural origin, that is to say that they are not synthetic and therefore come from the chemical or biotechnology industry. For this, the extract is obtained from Vaccinium macrocarpon, preferably from fruits, more preferably from Vaccinium macrocarpon cakes.

[0034] Vaccinium macrocarpon cakes are preferably obtained after a first step of extraction of the cranberry fruits allowing on the one hand to collect the cranberry juice and on the other hand the seeds and residual pulp from the fruit. The seeds and the pulp are then crushed and the oil extracted by cold pressing. Then the cranberry cake remains, the raw material of the extract according to the invention.

[0035] According to a preferred embodiment, the extract according to the invention is a hydrolysate of Vaccinium macrocarpon cakes, preferably an enzymatic hydrolysate of Vaccinium macrocarpon cakes.

[0036] Particularly advantageously, the enzymatic hydrolyzate is obtained after two successive enzymatic hydrolyses carried out by two different proteases.

[0037] The extract according to the invention then preferably comprises at least 80% of peptides by weight of dry matter of the extract. According to a particularly preferred embodiment, the peptides represent 98% by weight of dry matter of the extract. Said peptides have a size, expressed in molar mass, less than or equal to 2,000 Da. Preferably, said peptides have a size between 243 Da and 2,000 Da.

[0038] The distribution and quantity of the peptides can be determined by a spectrophotometric assay according to the Lowry method (Lowry et al., Protein measurement with the Folin reagent, J. Biol. Chem., 193, 265-275, 1951). The characterization and quantification of the amino acids present in the extract and therefore in the active ingredient according to the invention can be carried out by liquid chromatography after total hydrolysis of the sample.

[0039] Thus, the extract according to the invention is preferentially and predominantly composed of peptides comprising between 4 and 6 amino acids, said peptides being enriched in basic amino acids, preferentially at least 20%, more preferentially at least 25%, even more preferentially 27.9%, particularly in arginine, preferentially at least 15%, more preferentially 19.6%.

[0040] Thus, the extract according to the invention has a level of cationic peptides, said peptides being formed mainly of basic amino acids, greater than 20%.

[0041] The inventor also determined the dry matter content, ash content and total sugar content of the extract.

[0042] The dry matter content can be determined by weighing the residues resulting from drying the samples of the extract according to the invention at 105°C in an oven until a constant weight is obtained.

[0043] The mineral ash content can be determined by weighing the residues resulting from the incineration of the samples of the active ingredient according to the invention at 550°C in an electric muffle furnace.

[0044] The total sugar (carbohydrate) content in the active ingredient comprising said extract can be determined by the DUBOIS method (Dubois M. et al., Analytical chemistry, 28, 3, 350-356, 1956). The total sugar content in the active ingredient is expressed as a percentage relative to the dry matter.

[0045] The determination of total nitrogen in the extract according to the invention can be carried out in particular by the KJELDHAL method (reference: Official method of analysis of the AOC, 12th ed. W Horwitz, ED, New York, 15-60, 1975). The content is expressed as a percentage relative to the dry matter content.

[0046] The extract according to the invention preferably comprises 95% nitrogen fraction (i.e. peptides) and 5% ash, by weight relative to dry matter. It therefore does not include sugars.

[0047] The active ingredient according to the invention comprises the extract alone or with other constituents.

[0048] The cosmetic active ingredient according to the invention may be in liquid form or in solid form or in film form.

[0049] When it is in liquid form, the active ingredient according to the invention is preferably exclusively constituted by the extract of Vaccinium macrocarpon cakes accompanied by stabilizer and / or preservatives.

[0050] The extract in liquid form is preferably in the form of a clear liquid aqueous solution, with a weak odor and a very light yellow color. It can, however, be more colorful.

[0051] Preferably, the extract according to the invention in liquid form has a dry matter content of: 5 g / L to 30 g / L, even more preferably 9 g / L to 14 g / L.

[0052] When the active ingredient according to the invention is in solid form, it is preferably in powder form with or without a carrier. The carrier may, for example, be chosen from maltodextrins. In this case, preferably, the extract represents at least 5% by weight and the carrier at most 95% by weight.

[0053] The active ingredient according to the invention may also be presented in the form of a film. In this case, the extract of Vaccinium macrocarpon cakes preferably represents at least 0.1% by weight of the film.

[0054] When it is in the form of a film, the active ingredient comprises: - at least the hydrolyzate of Vaccinium macrocarpon oilcake according to the invention. - at least one mineral filler, and - at least one polymer of natural origin, and - at least one plasticizer, and - at least one surfactant, and

[0055] The polymer of natural origin can be chosen from: Pectin, Tamarind gum, Alginate, Pullulan, Psyllium, Xanthan, Guar, Tara, Carob, Agar, Gum arabic, Gellan, Dextran, Carrageenan, Cellulose, Konjac and Chitosan.

[0056] The plasticizer can be chosen from: Glycerol, Sorbitol, Sucrose, Erythritol, Urea, Propylene glycol and Butylene glycol.

[0057] The mineral filler can be chosen from: Calcium carbonate, green clay, kaolin, perlite, talc, magnesium silicate, mica, diatomaceous sericite, silica, calcium sulfate, calcium chloride, potassium chloride, iron oxide and zinc oxide.

[0058] The active ingredient may further comprise a pigment for coloring the film.

[0059] According to a preferred embodiment, the extract of the cosmetic active ingredient according to the invention is capable of being obtained by an extraction process comprising at least one enzymatic hydrolysis of Vaccinium macrocarpon cakes, the cakes having been previously solubilized in water.

[0060] According to a particularly preferred embodiment, the extract of the cosmetic active ingredient according to the invention is capable of being obtained by an extraction process comprising at least two enzymatic hydrolyses of Vaccinium macrocarpon cakes, the cakes having been previously solubilized in water.

[0061] Preferably, the two successive enzymatic hydrolyses are carried out with two different proteases. The method then preferably comprises sorting the molecules present in the soluble phase selected after hydrolysis, to purify the peptide fraction and particularly the peptides of sizes less than 2000 Da.

[0062] Thus, the extract of the cosmetic active ingredient according to the invention can be obtained by the following process: - solubilization of at least 100 g / L of Vaccinium Macrocarpon cake in water, - enzymatic hydrolysis, - purification of the peptide fraction.

[0063] According to a particularly preferred embodiment, the extract of the active ingredient according to the invention can be obtained by a process as described below.

[0064] Process for obtaining the extract according to the invention

[0065] The extract according to the invention can be obtained by any means.

[0066] According to a particularly suitable embodiment, the extract according to the invention is obtained by implementing the following steps: - Solubilization of Vaccinium macrocarpon fruits in water, preferably Vaccinium macrocarpon cakes, preferably at a rate of at least 100g of Vaccinium macrocarpon cakes per liter of water, - at least two successive enzymatic hydrolyses, preferably at least two enzymatic hydrolyses carried out using at least two different proteases, - separation of the soluble and insoluble phases, by any means allowing the separation of an insoluble phase from the soluble phase, for example by centrifugation, filtration or decantation, - recovery of the soluble phase, - enzymatic inactivation by any means allowing the inactivation of enzymatic activities, for example by heat treatment, - molecular sorting of the molecules from the soluble phase to recover the molecules of sizes less than 2000 Da and in particular peptides of sizes less than 2000 Da, preferably of sizes between 243 Da and 2000 Da, by any means allowing molecular sorting, for example by ultrafiltration or ion chromatography, - possibly deodorization or discoloration, - preferably filtration and sterilizing filtration.

[0067] During the extraction of cranberry juice, the seeds and pulp of the fruit remain. In a second step, during the extraction of the oil by cold pressing, only the cakes remain. This process is common in the food industry. These co-products are then reduced to powder. Thus, only the molecules of the fruit, preferably the cakes, constitute the starting raw material.

[0068] Molecular sorting can be carried out by ultrafiltration, preferably molecular sorting is carried out by ion chromatography.

[0069] An additional step for drying the hydrolyzate can be added so that it is in solid form, preferably in powder form. This can be an atomization or lyophilization step for example. In this case a support such as for example a maltodextrin can be used.

[0070] The steps of the processes described above, taken individually, are usual in the field of extractions of active ingredients from natural raw materials and those skilled in the art are able to adjust the reaction parameters on the basis of their general knowledge, and so as to obtain the characteristics of the active ingredient which is the subject of the invention.

[0071] Cosmetic composition

[0072] The active ingredient according to the invention is preferably used in cosmetic compositions comprising a physiologically acceptable medium, preferably a cosmetically acceptable medium. These are compositions of different galenic forms, suitable for topical application to the skin.

[0073] These compositions may be presented in particular in the form of oil-in-water emulsions, water-in-oil emulsions, multiple emulsions (Water / Oil / Water or Oil / Water / Oil) which may optionally be microemulsions or nanoemulsions, or in the form of solutions, suspensions, hydrodispersions, aqueous gels, powders, or foundations. They may be more or less fluid and have the appearance of creams, emulsions, gels, masks or any other aspects of healthy skin care cosmetics.

[0074] These may be compositions comprising at least 0.1% of the liquid active ingredient according to the invention (i.e. approximately 7.2 ppm of peptides), preferably between 0.5 and 10% or comprising at least 0.01% of a powder active ingredient according to the invention.

[0075] These compositions comprise, in addition to the active ingredient, a physiologically acceptable and preferably cosmetically acceptable, i.e. which does not cause feelings of discomfort for the user such as redness, tightness or tingling.

[0076] The compositions according to the invention may contain as adjuvant at least one compound chosen from: - oils, which may be chosen in particular from silicone oils, linear or cyclic, volatile or non-volatile, - waxes, such as ozokerite, polyethylene wax, beeswax or camauba wax, - silicone elastomers, - surfactants, preferably emulsifying surfactants, whether non-ionic, anionic, cationic or amphoteric, - co-surfactants, such as linear fatty alcohols, - thickeners and / or gelling agents, - humectants, such as polyols like glycerin, - colorants, preservatives, fillers, - tensors, - sequestrants, - perfumes, - and their mixtures, without this list being exhaustive.

[0077] Examples of such adjuvants are cited in particular in the CTFA Dictionary (International Cosmetic Ingredient Dictionary and Handbook published by the Personal Care Product Council).

[0078] Of course, those skilled in the art will take care to choose the possible complementary compounds, active or non-active, and their quantity, in such a way that the advantageous properties of the mixture are not, or not significantly, altered by the envisaged addition.

[0079] These compositions are intended to be used on healthy skin, in particular mature skin, in particular for an overall anti-aging effect, preferably an anti-wrinkle effect and / or to improve the radiance of the complexion and / or improve the quality of the dermo-epidermal junction, and / or improve cutaneous homeostasis.

[0080] The invention therefore also relates to a cosmetic process for treating the skin for an anti-wrinkle effect and / or to improve the radiance of the complexion and / or improve the quality of the dermo-epidermal junction, and / or improve cutaneous homeostasis which consists of the topical application to the skin of a healthy person of such an extract according to the invention or of such a composition according to the invention.

[0081] Use

[0082] The active ingredient according to the invention thus has characteristics which allow its use in cosmetics and in particular to limit the natural effects linked to aging and thus obtain an overall anti-aging effect, preferably an anti-wrinkle effect and / or to improve the radiance of the complexion and / or improve the quality of the dermo-epidermal junction, and / or improve cutaneous homeostasis.

[0083] It thus improves skin homeostasis and therefore the barrier function in healthy elderly subjects, which directly translates into a reduction in insensible water losses of 15%. Radiation is also increased by 14%, which results in a revived complexion. The epidermal barrier function of elderly skin is therefore reinforced.

[0084] The extract according to the invention also promotes the expression of major structural biomarkers of the dermis such as collagens I and III; periostin; tropoelastin; proteoglycans (decorin, perlecan, byglican, aggrecan); hyaluronic acid.

[0085] The extract according to the invention also makes it possible to reduce the expression of dermal degradation markers such as MMP-1.

[0086] Thus, the quality of the dermal fibers is improved by 17%, which results in a reduction in crow's feet wrinkles in Caucasian and Asian volunteers.

[0087] By acting on these different markers, the active ingredient according to the invention has a global anti-aging action. Consequently, the beauty and quality of the skin are enhanced, wrinkles are significantly reduced, the skin is firmer and the radiance of the complexion is revived. It is particularly suitable for mature healthy skin.

[0088] The active ingredient comprising at least one extract of Vaccinium macrocarpon oilcakes can thus be used for cosmetic and therefore by definition non-therapeutic, anti-aging uses in topical application to healthy skin.

[0089] The active ingredient differs from cranberry extracts commonly known for their antioxidant effect since it does not contain polyphenols giving it this effectiveness.

[0090] The invention is now illustrated by non-limiting examples of compositions according to the invention and by test results. Examples

[0091] Example 1: extract of Vaccinium macrocar not without extraction process according to the invention (Outside the Invention).

[0092] The characterization and quantification of the amino acids constituting a cranberry cake were carried out by liquid chromatography.

[0093] [Tables 1] Amino Acid Name Distribution (%) Alanine 5.0 Arginine 12.2 Aspartic Acid 10.8 Glutamic Acid 22.3 Cystine 0.0 Glycine 5.8 Histidine 2.2 Isoleucine 4.3 Leucine 7.9 Lysine 2.9 Phenylalanine 5.0 Proline 2.9 Serine 5.0 Threonine 3.6 Tyrosine 3.6

[0094] Cranberry cake has a basic amino acid content (arginine, histidine, lysine) of 17.3% and an acidic amino acid content (aspartic acid, glutamic acid) of 33.1%.

[0095] Example 2: Extract according to the invention

[0096] The active ingredient is obtained by implementing the following steps: - solubilization in water of Vaccinium macrocarpon cakes at a rate of 100 g / L, - enzymatic hydrolysis, - enzymatic inactivation by heat treatment, - a molecular sorting step by ion chromatography, intended to select molecules, in particular peptides, of sizes less than 2000 Da, - deodorization, - filtrations and sterilizing filtration.

[0097] The active ingredient obtained has the following analytical characteristics: - a dry matter content: 12.2 g / L - protein content: 10.2g / L (83.6%) - pH: 3.0 - 4.0 - an ash rate: 0.6g / L (4.9%).

[0098] The characterization and quantification of the amino acids constituting the extract according to the invention were carried out by liquid chromatography after hydrolysis of the sample.

[0099] The distribution of the different amino acids is presented in Table 2

[0100] [Tables2] Amino Acid Name Distribution (%) Alanine 6.2 Arginine 19.6 Aspartic Acid 10.3 Glutamic Acid 20.6 Cystine 0.0 Glycine 5.2 Histidine 3.1 Isoleucine 4.1 Leucine 8.2 Lysine 5.2 Phenylalanine 2.1 Proline 0.0 Serine 5.2 Threonine 3.1 Tyrosine 3.1

[0101] The extract according to the invention has a higher level of basic amino acids (27.9%) compared to the cranberry cake of example 1 due to a high arginine content and a lower level of acidic amino acids (30.9%) due to a reduction in the level of aspartic acid. The steps of the process according to the invention make it possible to select cationic peptides (rich in basic amino acids: arginine, histidine, lysine).

[0102] The active ingredient according to the invention does not have the characteristic often claimed by cranberry extracts, namely the active ingredient according to the invention does not have an anti-radical effect.

[0103] Indeed, the extract according to the invention does not exhibit any anti-radical activity according to the DPPH test as presented in Table 3 below.

[0104] Diphenyl-picrylhydrazylhydrate (DPPH) is a free radical, absorbing in the violet at 517nm. A free radical scavenger causes the violet color to disappear. The free radical scavenger activity of a substance is expressed as the percentage inhibition of DPPH absorbance.

[0105] [Tables3] Percentage of inhibition of DPPH absorbance Pure active ingredient 10% 50% of active ingredient 7% 10% of active ingredient 3%

[0106] At the maximum recommended dose, i.e. 10% of active ingredient, the percentage of inhibition of DPPH absorbance is low. Thus, the extract according to the invention does not exhibit any anti-radical activity.

[0107] Example 3: comparative example with extracts outside the invention (HI)

[0108] The following products are obtained from Vaccinium macrocarpon cakes using a process different from that of Example 2.

[0109] The product HI 1 is obtained with a process which differs from that of example 2 in that it does not contain a hydrolysis step.

[0110] The product obtained has the following analytical characteristics: - A dry matter content of 26.7 g / L - A protein content of 1.6 g / L (6%) - A sugar content of 11.4 g / L (57%)

[0111] The product therefore has a protein content of 6% relative to the dry matter content and therefore well below the minimum rate of 80% claimed within the framework of the invention.

[0112] The product HI 2 is obtained with a process which differs from that of example 2 in that it does not contain the molecular sorting steps.

[0113] The product obtained has the following analytical characteristics: - A dry matter content of 53.8 g / L - A protein content of 19 g / L (35%) - A sugar content of 17.3 g / L (32%)

[0114] The product has a protein content of 35% relative to the dry matter content and therefore lower than the minimum rate of 80%, claimed within the framework of the invention.

[0115] The effectiveness of the HI 2 extract and that of the present invention were studied in following the expression of genes linked to barrier function and matrix dynamics, following the protocol described below. The comparative results between the extract Outside the Invention and that of the present invention are presented in Table 4 below.

[0116] [T ables 4] Extract from Example 2 HI2 On aged keratinocytes Ki67 + + Claudinl + + IL8 ++ - loricrin + - On aged fibroblasts MMPI + + BGN + - AQP3 + -

[0117] It clearly appears that the HI 2 extract resulting from a different process and containing less than 80% of peptides, does not present an efficacy similar to that of the extract according to the invention for the expression of the genes studied.

[0118] Example 4: example of composition according to the invention

[0119] An example of a formulation comprising the active ingredient according to the invention in the form of a cream gel is presented in Table 5 below:

[0120] [Tables 5] Ingredients % A Water qs 100 Glycerin 2.00 Butylene Glycol 3.00 B Carbomer 0.30 C Aqua (Water) & Sodium Hydroxide 0.20 D Caprylyl Methicone 3.00 Dimethicone 3.00 Dimethicone & Dimethicone / Vinyl Dimethicone Crosspolymer 5.00 E Sodium Acryloyldimethyltaurate / VP Crosspolymer 0.75 F Preservative qs G Active ingredient invention 2.00 H Aqua (Water) & Sodium Hydroxide qs pH 7.0 - 7.5

[0121] The composition of Example 4 can in particular be obtained by the following process: - Disperse B in A with gentle stirring. - Pre-neutralize with C. - While stirring vigorously, add D then E. - Continue stirring for 20 minutes. - With moderate stirring, add F and G. - Adjust the pH with H.

[0122] The composition is then in the form of a thick, shiny, off-white cream gel with a pH at 1 month equal to 7.3, a viscosity (C / 5rpm) equal to 44,200 cP.

[0123] Example 5: example of composition according to the invention

[0124] An example of a formulation comprising an active ingredient according to the invention in the form of a smooth cream is presented in Table 6 below:

[0125] [Tableauxô] Ingredients % Al Water qs 100 Mono sodium Citrate 0.20 Preservative qs Erythritol 2.00 A2 Butylene Glycol 3.00 Distearate 0.50 Butyrospermum Parkii (Shea) Butter 2.00 Isocetyl Stearate 7.00 Cetearyl Ethylhexanoate 8.00 Diisopropyl Sebacate 4.00 Dimethicone 3.00 Argania Spinosa Kernel Oil 3.00 Tocopherol & Helianthus Annuus (Sunflower) Seed Oil 0.10 C Hydroxyethyl Acrylate / Sodium Acryloyldimethyl Taurate Copolymer 0.50 D Propylene Glycol 2.00 Alumina & CI 77891 (Titanium Dioxide) 1.00 E Active Principle of the invention 2.00 F Aqua (Water) & Sodium Hydroxide qs pH 5.0 - 6.0

[0126] The composition of Example 5 can in particular be obtained by the following process: - Add A2 to Al with moderate stirring, stir until a homogeneous gel is obtained and heat to 80°C. - Place B under magnetic stirring and heat to 80°C. - Emulsify B in A with a rotor-stator for 10 min. - At 50°C, with moderate stirring, add C, then D and E. - Cool to room temperature with gentle stirring, then adjust the pH with F.

[0127] The composition is then in the form of a thick, white, shiny emulsion, having a pH at 1 month equal to 6.0, a viscosity (C / 5rpm) equal to 57,000 cP.

[0128] Example 6: example of composition according to the invention

[0129] An example of a formulation comprising an active ingredient according to the invention under form of a night cream is presented in the following table 7:

[0130] [Paintings?] Ingredients % Al Water qs 100 Sodium Citrate 0.20 Preservative qs A2 Isopentyldiol 2.00 Glycerin 1.50 0.75 Cetearyl Alcohol 1.00 Hydrogenated Coconut Oil 2.00 Pentaerythrityl Tetraisostearate 3.00 Triheptanoin 3.00 Isopropyl Isostearate 6.00 Isopropyl Palmitate 6.00 Dimethicone 3.00 Tocopherol & Helianthus Annuus (Sunflower) Seed Oil 0.05 C Hydroxyethyl Acrylate / Sodium Acryloyldimethyl Taurate Copolymer & Polyisobutene & Aqua (Water) & PEG-7 Trimethylolpropane Coconut Ether & Sorbitan Isostearate 1.00 D Active Ingredient of the Invention 2.00

[0131] The composition of Example 6 can in particular be obtained by the following process: - Add A2 to Al with moderate stirring, stir until a homogeneous gel is obtained and heat to 80°C. - Place B under magnetic stirring and heat to 80°C. - Emulsify B in A under shearing agitation for 10 min. - At 40-50°C, with moderate stirring, add C, then D.

[0132] The composition is then in the form of a thick, white, shiny emulsion.

[0133] Example 7: example of composition according to the invention

[0134] An example of a formulation comprising an active ingredient according to the invention under form of a foundation is presented in the following table 8:

[0135] [Tables8] Ingredients % A Polyglyceryl-3 Polyricinoleate & Poly-glyceryl-3 Diisostearate 5.00 Hydrogenated Castor Oil 0.50 Cera Alba (Beeswax) 0.50 Dicaprylyl Carbonate & Stearalkonium Hectorite & Propylene Carbonate 6.00 Isononyl Isononanoate 4.00 Dimethicone 4.00 Triheptanoin 4.00 C12-15 Alkyl Benzoate 4.00 Magnesium Stearate 1.00 B Cocoglycerides 12.00 CI 77499 (Iron Oxides) & Hydrogenated Lecithin 0.10 CI 77491 (Iron Oxides) & CI 77499 (Iron Oxides) & Hydrogenated Lecithin 0.50 CI 77891 (Titanium Dioxide) & Hydrogenated Lecithin 8.00 CI 77492 (Iron Oxides) & Hydrogenated Lecithin 1.00 C Aqua (Water) qsp 100 Glycerin 5.00 Magnesium Sulfate 1.00 Preservative qs Polyglyceryl-3 Polyricinoleate & Poly-glyceryl-3 Diisostearate D Active Principle of the Invention 2.00

[0136] The composition of Example 7 can in particular be obtained by the following process: - Heat A to 85°C and homogenize with vigorous stirring. - Grind B in a three-cylinder mill and transfer to A. Shake until smooth. - Place C under magnetic stirring and heat to 80°C. - Add C to AB very slowly while stirring vigorously. - Homogenize for 10 minutes under shearing agitation. - At 30°C, add D and homogenize for 2 min with continuous stirring.

[0137] The composition is then in the form of a flexible and shiny emulsion.

[0138] Efficacy tests

[0139] Test 1: Evaluation of the potential activity of the active ingredient according to the invention on the major genes of cutaneous homeostasis

[0140] The objective of this study is to evaluate the potential activity of the active ingredient according to the invention on the major genes involved in skin balance.

[0141] This study was carried out on 34 genes involved in the different processes linked to the establishment of: - the epidermal barrier function: proliferation, hydration, cohesion, differentiation, desquamation, innate immunity, antioxidant system and inflammation (see Table 9: Proliferation, Hydration, Cohesion, Differentiation, Anti-radical and Inflammation). - the dermo-epidermal junction JDE; - the dermal matrix: organization and degradation of fibers, hydration and inflammation (see Table 9: Matrix organization, matrix degradation, Hydration, Proteoglycan, Growth factors and Inflammation).

[0142] The expression of the different targeted genes was evaluated by quantitative PCR on human keratinocytes from young (< 30 years) and old (> 60 years) donors or young (< P5) and old human fibroblasts by successive replications (more than 20 replications).

[0143] The operating protocol of the study is described as follows. Young and old human cells are seeded and incubated at 37°C. Then, the cells are treated for 48 hours with the active ingredient according to the invention or a 0.5.10-5M retinol solution.

[0144] After several days, the cells were recovered and the total RNAs extracted. The RNAs were reverse-transcribed and the complementary DNAs obtained were analyzed by the quantitative PCR technique. The mRNAs of internal reference controls were analyzed in parallel with the mRNAs of the markers involved in the barrier function of the epidermis, in the DEJ and in the dermal matrix.

[0145] Fluorescence incorporation is continuously measured using a thermocycler. Ct analysis (relative quantification) is performed using software.

[0146] The results are presented in Table 9.

[0147] [Tables 9] Young cells Old cells Genes Control Control n Active ingredient of example 2 0.5% PA efficacy / Aged control (%) Retino 1 1 pM Retinol efficacy / Aged control (%) Proliferation MKI6 7 100 66 93 +41 95 +44 Hydration AQP3 100 61 84 +38 69 +13 HAS3 100 68 101 +49 357 +425 CD44 100 83 104 +25 147 +77 Cohesion CLD NI 100 69 90 +30 33 -52 DSG 100 72 85 +18 1 -99 Differentiation FLG 100 38 56 +47 9 -76 LOR 100 20 35 +75 1 -95 TGM 1 100 68 89 +31 47 -31 KRT1 0 100 73 91 +25 2 -97 IVL 100 53 64 +21 120 +126 S100 A7 100 38 50 +32 564 +1384 Anti-radical SOD1 100 89 100 + 12 95 +7 Inflammation CXCL 8 100 252 161 -36 729 +189 S100 A8 100 208 186 -11 256 +23 S100 A9 100 191 177 -7 397 +108 Structural elements of the JDE LAM A3 100 103 114 + 11 94 -9 COL4 Al 100 40 54 +35 38 -5 COL7 Al 100 86 105 +22 68 -21 COL1 7A1 100 97 113 +16 81 -16 Matrix organization COL1 Al 100 63 78 +24 79 +25 COL3 Al 100 43 53 +23 72 +67 POST N 100 45 43 -4 56 +24 ELN 100 60 77 +28 63 +5 FBN1 100 91 99 +9 90 -1 Matrix degradation MMP 1 100 216 136 -37 164 -24 Hydration AQP3 100 56 98 +75 73 +30 Proteoglycan HSPG 2 100 87 87 0 90 +3 BGN 100 63 77 +22 78 +24 DCN 100 83 91 +10 89 +7 ACA N 100 38 45 +18 10 -74 LUM 100 90 94 +4 87 -3 Growth factors VEGF A 100 91 88 -3 93 +2 TGF[3 1 100 95 97 +2 103 +8 Inflammation CXCL 8 100 210 185 -12 803 +282 IL1 100 226 160 -29 567 +151

[0148]

[0149]

[0150]

[0151]

[0152]

[0153] Of the 34 genes evaluated, 76% show modified expression during aging, reflecting a major impact on barrier function, the dermo-epidermal junction and the dermal matrix. Tested at 0.5% on aged keratinocytes, the active ingredient according to the invention significantly restores the expression of key genes of: - proliferation (Ki67: + 41%); - differentiation (loricrin: +75% and filaggrin: +47%); - cohesion (claudine-1: +30%); - anti-radical defense (SOD1: +12%). Tested at 0.5% on aged fibroblasts, the principle according to the invention acts significantly on the expression of genes linked to matrix organization (collagen 1: +24% and elastin: +28%) and its degradation (MMPI: -37%). On both cell types, a significant action was demonstrated on markers linked to hydration and inflammation. The active principle according to the invention and retinol have similar effects on genes linked to the matrix. Test 2: Biological efficacy of the active ingredient according to the invention on the barrier function of the epidermis and hydration. The objective of this study is to evaluate the capacity of the active ingredient according to the invention to maintain a functional barrier function by stimulating the synthesis of Ki 67, loricrin, claudin-1 and aquaporin 3. One of the skin's major strategies to protect itself is to maintain a barrier intact. This barrier, resulting from the process of proliferation and differentiation of keratinocytes, results from the particular structure of the stratum corneum and the cohesion of the upper layers of the epidermis ensured by tight junctions. Several protein components are essential for the establishment of this barrier function such as: - Ki-67 which is a key marker of proliferation of cells in the basal layer of the epidermis. - Loricrin which plays a major role in terminal differentiation. - Claudin-1 which is one of the main constituents of tight junctions, complex structures which establish true cell-cell cohesion. - Aquaporin 3, which is one of the membrane proteins essential for water transport and helps maintain hydration of the stratum corneum.

[0154] Proliferation, cohesion and hydration level are thus directly linked to the epidermal differentiation process and the state of the barrier function.

[0155] This study was carried out on normal and aged reconstructed epidermis. Epidermal construction was assessed using Hematoxylin Eosin (HE) staining and the synthesis of barrier function markers by immunohistofluorescence.

[0156] The operating protocol of the study is described as follows. Young and old human keratinocytes are seeded onto inserts and then incubated at 37°C in an atmosphere containing 5% CO2 and cultured for several days.

[0157] The reconstructed epidermis are treated for 48 hours systemically with: - The active ingredient according to the invention at 0.1% and 0.5% (V / V) - A 10 pM retinol solution.

[0158] The reconstructed epidermis are recovered, fixed, dehydrated and embedded in paraffin. Sections (4 μm) are then made using a microtome.

[0159] Analysis of the thickness of the reconstructed epidermis is carried out by hematoxylin eosin (HE) staining.

[0160] Analysis of the synthesis of Ki67, claudin-1, aquaporin 3 and loricrin is carried out by immunohistofluorescence.

[0161] Visualization is carried out using a microscope coupled with an image analysis system. The thickness of the epidermis obtained was measured on the histological sections produced.

[0162] The rate of the different synthesized markers is proportional to the intensity of green fluorescence present on the reconstructed epidermis. A quantitative analysis of the images was carried out using an image analysis script. The results are expressed in arbitrary units (AU).

[0163] The results concerning the capacity of the active ingredient according to the invention and of retinol to restoring epidermal thickness are presented in Table 10.

[0164] [Tables 10] Measurement of epidermal thickness (pm) Capacity to restore epidermal thickness (%) young reconstructed epidermis Control 60 old reconstructed epidermis Control 44 Active ingredient 0.1% 54 +63 Active ingredient 0.5% 60 +100 Retinol 10 pM 59 +94

[0165] The results concerning the capacity of the active principle according to the invention to restore the synthesis of Ki-67 are presented in Table 11.

[0166] [T ables 11] Ki-67 positive cells (%) Capacity to restore Ki-67 synthesis (%) young reconstructed epidermis Control 27 aged reconstructed epidermis Control 13 Active ingredient 0.1% 21 +57 Active ingredient 0.5% 25 +86 Retinol 10 pM 23 +71

[0167] The results concerning the capacity of the active ingredient according to the invention to restore the synthesis of loricrin are presented in Table 12. [Tables 12] Loricrin synthesis (xlO4 UA) Capacity to restore loricrin synthesis (%) young reconstructed epidermis Control 372 old reconstructed epidermis Control 191 Active ingredient 0.1% 256 +36 Active ingredient 0.5% 279 +49 Retinol 10 pM 177 0

[0169] The results concerning the capacity of the active principle according to the invention to restore the synthesis of claudin-1 are presented in Table 13.

[0170] [Tablesl3] Claudin-1 synthesis (xlO4 UA) Capacity to restore claudin-1 synthesis (%) young reconstructed epidermis Control 270 aged reconstructed epidermis Control 180 Active ingredient 0.1% 223 +48 Active ingredient 0.5% 243 +70 Retinol 10 pM 136 0

[0171] The results concerning the capacity of the active principle according to the invention to restore the synthesis of aquaporin 3 are presented in table 14. [Tables 14] Aquaporin 3 synthesis (xlO4 UA) Capacity to restore aquaporin 3 synthesis (%) young reconstructed epidermis Control 355 aged reconstructed epidermis Control 249 Active ingredient 0.1% 308* +56 Active ingredient 0.5% 327* +74 Retinol 10 pM 355** +100

[0173]

[0174]

[0175]

[0176]

[0177]

[0178] Aged reconstructed epidermis exhibit impaired barrier function, characterized by a significant decrease in epidermal thickness, synthesis of Ki-67, loricrin, claudin-1, and aquaporin 3. Tested at 0.50% on aged reconstructed epidermis, the active ingredient according to the invention significantly restores the thickness of the epidermis and the synthesis of: Ki-67 by +86%; - loricrin of +49%; - Claudine-1 of +70%; - aquaporin 3 by +74%. The active ingredient according to the invention thus makes it possible to maintain a functional and hydrated barrier. Test 3: Biological efficacy of the active ingredient according to the invention on matrix dynamics. The objective of this study is to evaluate the capacity of the active ingredient according to the invention to promote the production of a functional matrix network. The dermal extracellular matrix is ​​composed mainly of a dense network of collagen I fibers. This collagen plays a key role in all phases of tissue remodeling. From the age of 50, the quality of the dermis gradually deteriorates. The network of collagen fibers becomes less and less dense and more and more fragmented. This effect is notably attributable to the increase in matrix metalloproteinase MMP-1, which degrades collagen I and III fibers. Furthermore, hyaluronic acid is essential for maintaining the structure of the skin's layers. It combines with water and fills the intercellular spaces, which contributes to its highly moisturizing power. The quantity and quality of hyaluronic acid, the main glycosaminoglycan in the dermis, gradually decreases with age.

[0179] The effect of the active ingredient according to the invention on: - the collagen I network was studied by immunocytology, on young (P5) and old (P22) human fibroblasts obtained by successive replications; - the MMP 1 level was measured by ELISA assay on human fibroblasts from donors aged over 60 years and subjected to UVA exposure; - hyaluronic acid synthesis was assessed by ELISA assay on human fibroblasts from donors aged over 60 years

[0180] Study of the collagen I network

[0181] Human fibroblasts are seeded and incubated at 37°C in an atmosphere containing 5% CO2.

[0182] Cells are treated every two days with: - The active ingredient according to the invention at 0.05% and 0.10% (V / V) - a 0.1 µM retinol solution

[0183] They are then incubated in an atmosphere containing 5% CO2 at 37°C.

[0184] Immunocytological labeling of collagen I is carried out by fixation and permeabilization using primary antibody I and secondary antibody coupled to a fluorophore.

[0185] A quantitative analysis was carried out by reading the fluorescence of the different conditions tested using a fluorimeter. The intensity of the collagen I network is proportional to the intensity of green fluorescence present. The results are expressed in fluorescence value (AU).

[0186] Study of the MMP-1 rate

[0187] Aged human fibroblasts are seeded and incubated at 37°C in an atmosphere containing 5% CO2. Irradiation is carried out using a UV lamp with UVA intensities of 10 J / cm2.

[0188] The culture medium is replaced by medium containing: - The active ingredient according to the invention at 0.5% and 1% (V / V) - A retinol solution at IpM

[0189] The cells are then incubated at 37°C in an atmosphere containing 5% CO2 for 48 hours.

[0190] Study of the hyaluronic acid level

[0191] Aged human fibroblasts are seeded and incubated at 37°C in an atmosphere containing 5% CO2.

[0192] The culture medium is replaced by medium containing: - The active ingredient according to the invention at 0.5% and 1% (V / V) - a retinol solution at IpM

[0193] The cells are then incubated at 37°C in an atmosphere containing 5% CO2 for 48 hours.

[0194] The results concerning the capacity of the active ingredient according to the invention and of retinol to restore the synthesis of the collagen I network in aged fibroblasts are presented in Table 15.

[0195] [Tablesl5] Synthesis of collagen I network (xlO3 UA) Capacity to restore synthesis of collagen I network (%) Young fibroblasts Control 240 Old fibroblasts Control 177 Active ingredient 0.05% 194 +27 Active ingredient 0.10% 211 +54 Retinol 0.1 pM 174

[0196] The results concerning the effect of the active ingredient according to the invention on the synthesis of MMP-1 by aged human fibroblasts subjected to UVA irradiation are presented in Table 16.

[0197] [Tableauxlô] MMP-1 level (ng / mg protein) Capacity to reduce MMP-1 level (%) Non-irradiated fibroblasts Control 12 Irradiated fibroblasts Control 63 Active ingredient 0.5% 41 +43 Active ingredient 1% 40 +45 Retinol 1 pM 46 +33

[0198] The results concerning the effect of the active ingredient according to the invention on the synthesis of hyaluronic acid by aged human fibroblasts subjected to UVA irradiation are presented in Table 17.

[0199]

[0200]

[0201]

[0202]

[0203]

[0204]

[0205]

[0206]

[0207]

[0208] [Tables 17] Hyaluronic acid synthesis (ng / mg protein) Hyaluronic acid level / Control (%) Aged fibroblasts Control 3804 Active ingredient 0.5% 4678 + 23 Active ingredient 1% 5066 + 33 Retinol 1 pM 4112 + 8 Aged fibroblasts exhibit an altered matrix network, characterized by a significant decrease in the collagen I network and hyaluronic acid synthesis. In response to UVA irradiation, they significantly produce MMP-1. Tested at 0.1%, the active ingredient according to the invention: - significantly increases the production of the collagen I network by 54%. Tested at 1%, the active ingredient according to the invention: - significantly decreases the synthesis of MMP-1 by irradiated aged fibroblasts by 45%. - significantly increases hyaluronic acid synthesis by 33%. The active ingredient according to the invention thus maintains a functional organization of the matrix fibers and contributes to hydration in the dermis. Test 4: Cosmetic efficacy of the active ingredient according to the invention evaluated in healthy Caucasian and Asian volunteers (in vivo test). The objective of this study is to evaluate in vivo the cosmetic benefits of the active ingredient according to the invention formulated at 2% in emulsion, in comparison with a placebo formula, in Caucasian and Asian volunteers. The Caucasian panel is composed of 2 groups of healthy female volunteers, aged 45 to 66 years, presenting crow's feet wrinkles and having applied the placebo and the active ingredient according to the invention 2% on half-face in a randomized and twice-daily manner for 42 days. The cosmetic benefits of the active ingredient according to the invention were evaluated on a Caucasian panel on the face, after 21 and 42 days of twice-daily application, according to the following methods: - Study of the radiance of the complexion by visual scoring by experts (radiance, pink color, olive color, state of eye fatigue) - Study of the anti-wrinkle effect by projection of fringes. The Asian panel is composed of 2 groups of healthy female volunteers, presenting crow's feet wrinkles and a dull complexion, having applied either the active ingredient of the invention at 2%, i.e. the placebo, on the entire face, twice daily for 42 days.

[0209] The cosmetic benefits of the active ingredient of the invention were evaluated on an Asian panel on the face, after 21 and 42 days of twice-daily application, according to the following methods: - Study of complexion radiance by clinical scoring. - Study of the anti-wrinkle effect by clinical scoring.

[0210] A) Effect of the active ingredient according to the invention on the radiance of the complexion

[0211] The active ingredient according to the invention formulated at 2% in emulsion, improves the pa characteristic parameters of complexion radiance in Caucasian subjects. This effect appears significantly and significantly after 21 days.

[0212] Indeed, compared to the placebo, the active ingredient according to the invention: - gives a brighter and fresher complexion by significantly increasing skin radiance by 12%. This effect was observed in 89% of volunteers and increases after 42 days of treatment (+14%) in 88% of volunteers. - also significantly increases the pink color by 17%. This effect was observed in 61% of volunteers and increases after 42 days of treatment (+22%) in 82% of volunteers. - significantly reduces olive color by 8%. This effect was observed in 61% of volunteers and intensifies after 42 days of treatment (-12%) in 88% of volunteers. - also reduces eye fatigue by 8%. This effect was observed in 72% of volunteers and intensifies after 42 days of treatment (-10%) in 82% of subjects.

[0213] The active ingredient according to the invention formulated at 2% in emulsion also improves the characteristic parameters of complexion radiance in Asian subjects. This effect appears significantly from 21 days and intensifies after 42 days of treatment.

[0214] Indeed, compared to the placebo, the active ingredient according to the invention: - significantly increases skin radiance by 5%, this effect improves further after 42 days of treatment (+10%) - increases brightness by 6%, this effect improves further after 42 days of treatment (+8%), - increases the pink color, linked to the freshness of the complexion by 9%, this effect increases after 42 days of treatment by 18%. - causes a decrease in olive color (-5%), this parameter decreases further after 42 days of treatment by 12%.

[0215] These effects were observed in 97% of volunteers.

[0216] B) Anti-wrinkle effect of the active ingredient according to the invention

[0217] The active ingredient according to the invention formulated at 2% exhibits a rapid and significant anti-wrinkle effect in Caucasian subjects from 21 days of twice-daily use.

[0218] Indeed, in comparison with the placebo, the active ingredient according to the invention: - smoothes the skin relief of crow's feet by significantly reducing skin roughness after 21 days (parameter Sa = -6%). This effect is maintained after 42 days of use (Sa = -7%). - reduces wrinkles by allowing a reduction in the negative volume parameter (-22% after 21 days of treatment and -19% after 42 days).

[0219] The study of the distribution of results shows an improvement in these parameters in 83% of subjects.

[0220] Similarly, the active ingredient according to the invention formulated at 2% exhibits a rapid and significant anti-wrinkle effect in Asian subjects after 21 days of twice-daily use.

[0221] Indeed, compared to the placebo, the active ingredient according to the invention reduces the stage of crow's feet wrinkles by 10%, starting from 21 days of treatment. This effect intensifies after 42 days of use (reduction in the stage of wrinkles by 20%). This effect was observed in 53% and 84% of volunteers respectively.

[0222] Test 5: Efficacy of the active ingredient according to the invention on the skin barrier in healthy Caucasian and Asian volunteers.

[0223] The objective of this study is to evaluate in vivo the effect of the active ingredient according to the invention, formulated at 2.5% in emulsion, on the quality of the skin barrier, in comparison with a placebo formula, in Caucasian and Asian volunteers.

[0224] The Caucasian panel is composed of two groups of 18 healthy female volunteers, aged 45 to 66, presenting crow's feet wrinkles and having applied morning and evening the active ingredient according to the invention and the placebo on half of the face in a randomized and twice-daily manner for 42 days.

[0225] The Asian panel is composed of two groups of 32 healthy female volunteers, aged between 41 and 64 years, who applied morning and evening either the active ingredient according to the invention or the placebo to the entire face for 42 days.

[0226] Transepidermal Water Loss (TEWL) measurements at the cheeks were carried out using a Tewamètre® before and after 21 and 42 days of twice-daily application.

[0227] From 21 days of twice-daily application and in comparison with the placebo group, the active ingredient according to the invention formulated at 2% in emulsion significantly improves the quality of the skin barrier of Caucasian volunteers (reduction of water loss of 17%). This reduction was observed in 94% of the volunteers.

[0228] This effect is maintained after 42 days of treatment with a decrease in TEWL equal to 15% and is observed in 82% of subjects.

[0229] From 21 days of twice-daily application to the entire face and in comparison to placebo group, the active ingredient according to the invention formulated at 2% in emulsion significantly improved the quality of the skin barrier of Asian volunteers by reducing insensible water losses by 13%. This reduction was observed in 55% of the volunteers.

[0230] This effect intensifies after 42 days of treatment with a decrease in TEWL equal to 15% and is observed in 71% of subjects.

[0231] By reducing water loss, the active ingredient according to the invention tested at 2% promotes the strengthening of the skin barrier of Caucasian and Asian volunteers.

[0232] Test 6: Efficacy of the active ingredient according to the invention on the quality of the dermo-epidermal junction in healthy Caucasian volunteers.

[0233] The objective of this study is to evaluate in vivo the effect of the active ingredient according to the invention formulated at 2% in emulsion, on the quality of the DEJ zone, an area essential for exchanges between the dermis and the epidermis, in comparison with a placebo formula, in Caucasian volunteers.

[0234] The Caucasian panel is composed of 2 groups of 18 healthy female volunteers, aged 45 to 66 years, presenting crow's feet wrinkles and having applied the placebo and the active ingredient according to the invention 2% on half-face in a randomized and twice-daily manner for 42 days.

[0235] The effect of the active ingredient according to the invention on the quality of the Dermo-Epidermal Junction (DEJ) area was evaluated at the level of the cheeks, in comparison with the placebo, after 21 and 42 days of twice-daily application, by studying the structure of the dermo-epidermal junction (LC-OCT).

[0236] Compared to the placebo, the active ingredient according to the invention formulated at 2% in emulsion promotes the sinusoidal aspect of the DEJ. This effect appears after 21 days of twice-daily application (+3%, effect observed in 78% of volunteers) and intensifies significantly after 42 days of treatment (+4%, effect observed in 88% of volunteers).

[0237] By improving the sinuosity of the DEJ, the active ingredient according to the invention increases the surface area of ​​the DEJ and thus promotes exchanges between the epidermis and the dermis and its involvement in resistance to mechanical stress.

[0238] Efficacy of the active ingredient according to the invention on the quality of the dermal matrix in healthy Caucasian volunteers.

[0239] The objective of this study is to evaluate in vivo the effect of the active ingredient according to the invention formulated at 2% in emulsion on the quality of the dermal matrix, in comparison with a placebo formula, in Caucasian volunteers.

[0240] The Caucasian panel is composed of 2 groups of 18 healthy female volunteers, aged 45 to 66 years, presenting crow's feet wrinkles and having applied the placebo and the active ingredient according to the invention 2% on half-face in a randomized manner. and twice daily for 42 days.

[0241] The effect of the active ingredient according to the invention on the quality of the dermal matrix was evaluated at the level of the cheeks, in comparison with the placebo, after 21 and 42 days of twice-daily application, by studying the quality of the fibers (LC-OCT).

[0242] From 21 days of twice-daily application and in comparison with the placebo group, the active ingredient according to the invention formulated at 2% in emulsion, improves the quality of the fibers for all Caucasian volunteers by 15%. This effect is maintained after 42 days of treatment (+11%) and was observed in 94% of the volunteers.

[0243] By strengthening the support tissue, the active ingredient according to the invention thus limits the sagging of the skin.

[0244] Test 7: Comparative test between the active ingredient according to the invention and a reference molecule: retinol.

[0245] The objective of this study is to evaluate in vivo the cosmetic benefits of the active ingredient according to the invention formulated at 2% in emulsion in Caucasian volunteers in comparison with a reference molecule, retinol formulated at 0.075%.

[0246] This study was conducted on 3 groups of 18 healthy female volunteers, aged 45 to 66 years, with crow's feet wrinkles. Each volunteer applied two of the three formulas to half the face in a randomized, twice-daily fashion for 42 days.

[0247] The study of cosmetic benefits was carried out after 21 and 42 days of treatment according to the following methods: - Study of the radiance of the complexion by visual scoring by experts. - Study of the anti-wrinkle action by projection of fringes.

[0248] Study of the radiance of the complexion

[0249] The radiance of the complexion is evaluated by experts according to the following parameters: radiance, pink color, olive color and the state of eye fatigue.

[0250] The results are shown in Table 17.

[0251] [Tables 18] J21 J42 Retinol 0.075% Active ingredient Invention at 2% Retinol 0.075% Active ingredient Invention at 2% Radiation +6% +12% +11% +14% Pink color + 14% +17% +19% +22% Olive color -11% -8% -10% -12% Eye fatigue -2% -8% -10% -10%

[0252] The active ingredient according to the invention has a faster effect than retinol on the parameters of radiation, pink color and eye fatigue than retinol alone from D21. This effect intensifies after 42 days of use.

[0253] Study of the anti-wrinkle effect

[0254] The anti-wrinkle effect is evaluated according to the roughness parameter Sa, evaluated on the crow's feet area by fringe projection and on the negative volume, evaluated on the same area.

[0255] The results are presented in Table 19.

[0256] [Tablesl9] D21 D42 Retinol 0.075% Active ingredient Invention at 2% Retinol 0.075% Active ingredient Invention at 2% Parameter Sa -5% -6% -7% -7% Negative volume -12% -22% -20% -19%

[0257] Compared to placebo, retinol formulated at 0.075% tends to reduce crow's feet wrinkles after 21 days of treatment (non-significant difference). It is only after 42 days of treatment that retinol begins to show a significant anti-wrinkle effect (-20%).

[0258] Under the same conditions, the active ingredient according to the invention exhibits a significantly greater anti-wrinkle effect from 21 days (respectively -22%). This effect is maintained after 42 days of application, (-19%).

[0259] The active ingredient according to the invention has a rapid anti-wrinkle effect, it makes it possible to obtain an effect comparable to retinol alone.

[0260] Test 8: Study of the quality of the dermo-epidermal junction.

[0261] The objective of this study is to evaluate in vivo the effect of the active ingredient according to the invention formulated at 2% in emulsion on the quality of the DEJ zone, an area essential for exchanges between the dermis and the epidermis in Caucasian volunteers in comparison with a reference molecule, retinol formulated at 0.075%.

[0262] This study was conducted on 3 groups of 18 healthy female volunteers, aged 45 to 66 years, with crow's feet wrinkles. Each volunteer applied two of the three study formulas to half of their face in a randomized, twice-daily fashion for 42 days.

[0263] Acquisitions made by LC-OCT after 21 and 42 days of treatment at the cheek level made it possible to evaluate the structure of the dermo-epidermal junction.

[0264] A summary of the results corresponding to the effect of the different formulas under study on the sinuosity of the JDE, studied by LC-OCT, is presented in Table 20.

[0265] [Tables20] J21 J42 Retinol 0.075% Active ingredient Invention at 2% Retinol 0.075% Active ingredient Invention at 2% Sinuosity +2% +3% +3% +4%

[0266] The active ingredient according to the invention formulated at 2% or retinol at 0.075% show similar results compared to the placebo.

[0267] From 21 days of application the sinuosity of the JDE is intensified (active ingredient according to the invention: +3%; retinol: +2%). This effect becomes significant after 42 days of application (active ingredient according to the invention: +4%; retinol: +3%).

[0268] Test 9: Study of the quality of the dermal matrix

[0269] The objective of this study is to evaluate in vivo the effect of the active ingredient according to the invention formulated at 2% in emulsion on the quality of the dermal matrix in Caucasian volunteers in comparison with a reference molecule, retinol formulated at 0.075%.

[0270] This study was conducted on 3 groups of 18 healthy female volunteers, aged 45 to 66 years, with crow's feet wrinkles. Each volunteer applied two of the three study formulas to half of their face in a randomized, twice-daily fashion for 42 days.

[0271] Acquisitions made by LC-OCT after 21 and 42 days of treatment at the cheek level made it possible to evaluate the structure of the quality of the fibers.

[0272] The results corresponding to the effect of the different formulas under study on the quality of the fibers, studied by LC-OCT are presented in Table 21.

[0273] [Tables21] J21 J42 Retinol 0.075% Active ingredient Invention at 2% Retinol 0.075% Active ingredient Invention at 2% Fiber quality +3% +15% +12% +11%

[0274] From 21 days, compared to the placebo, the active ingredient according to the invention at 2% significantly improves the quality of the fibers (+15%). At this time, this improvement is not visible in the group having applied retinol at 0.075% (+3%, not significant).

[0275] After 42 days of treatment, the active ingredient according to the invention and retinol show comparable improvements.

[0276] Thus, the active ingredient according to the invention improves the quality of the fibers and does so significantly more quickly than retinol (significant difference at 21 days, p=0.0020).

[0277] Trial 10: Study of adverse effects.

[0278] The use of retinol is accompanied by undesirable effects such as an alteration in the quality of the barrier function and phenomena of skin irritation.

[0279] The objective of this study is to evaluate in vivo the capacity of the active ingredient according to the invention formulated at 2% in emulsion and of retinol formulated at 0.075% on the adverse effects of retinol in Caucasian volunteers.

[0280] This study was conducted on 3 groups of 18 healthy female volunteers, aged 45 to 66 years, with crow's feet wrinkles. Each volunteer applied two of the three formulas, on half of the face, in a randomized, twice-daily fashion for 42 days.

[0281] The effects of the active ingredient according to the invention and of retinol were observed according to the following methods: - Study of the barrier function (Téwamètre®) - Study of skin irritations (C-Cube) - Recording of skin reactions occurring during the study

[0282] The results corresponding to the effect of the different formulas on the barrier function and on skin irritations are presented in Table 22.

[0283] [Tables22] D21 D42 Retinol 0.075% Active ingredient Invention at 2% Retinol 0.075% Active ingredient Invention at 2% Water loss +24% -17% +15% -15% Parameter a* +5% +1% +5% 0%

[0284] Compared to the placebo, the formula containing retinol formulated at 0.075% leads to a reduction in water loss, thus preserving the quality of the skin barrier. Conversely, retinol formulated at 0.075% causes an increase in water loss (+24% at D21 and +15% at D42).

[0285] From 21 days of treatment, the application of the formula containing 0.075% retinol significantly increases the parameter a*, thus reflecting the appearance of skin redness. Compared to retinol, the active ingredient according to the invention at 2% does not cause the appearance of redness after 42 days of use.

[0286] Finally, in the placebo group (18 volunteers included) and in the group of the active ingredient according to the invention (18 volunteers included) no subject manifested an adverse effect. In the retinol group (18 volunteers included), three subjects manifested adverse effects with a “likely” imputability to the product under study. The incident rate in this group represents 17%.

[0287] Under the conditions of this study, after 21 days of treatment, the formula containing retinol caused adverse effects.

[0288] No adverse effects were recorded with the formula containing the active ingredient according to the invention at 2%.

Claims

Claims

1. Cosmetic active ingredient comprising at least one extract of Vaccinium macrocarpon characterized in that said extract comprises at least 80% of peptides by weight of dry matter of the extract.

2. Cosmetic active ingredient according to the preceding claim, characterized in that said extract is obtained from the fruit of Vaccinium macrocarapon.

3. Cosmetic active ingredient according to one of the preceding claims, characterized in that said extract is obtained from Vaccinium Macrocarpon cakes.

4. Cosmetic active ingredient according to one of the preceding claims, characterized in that the extract is a hydrolyzate of Vaccinium Macrocarpon.

5. Cosmetic active ingredient according to the preceding claim, characterized in that the hydrolyzate is an enzymatic hydrolyzate.

6. Cosmetic active ingredient according to one of claims 4 or 5, characterized in that the hydrolyzate comprises at least 80% of peptides, by weight of dry matter of the extract, said peptides having a size less than or equal to 2,000 Da.

7. Cosmetic active ingredient according to the preceding claim, characterized in that the size is between 243 and 2,000 Da.

8. Cosmetic active ingredient according to one of the preceding claims, characterized in that the peptides present in the hydrolyzate comprise on average between 4 and 6 amino acids.

9. Cosmetic active ingredient according to the preceding claim, characterized in that said extract has a level of cationic peptides rich in basic amino acids greater than 20%.

10. Cosmetic active ingredient according to one of the preceding claims, characterized in that said extract is capable of being obtained by a process comprising the following steps: - solubilization of at least 100 g / L of Vaccinium Macrocarpon cakes in water, - enzymatic hydrolysis, - purification of the peptide fraction.

11. Cosmetic active ingredient according to one of the preceding claims, characterized in that said extract is capable of being obtained by an extraction process comprising two enzymatic hydrolyses of Vaccinium Macrocarpon cakes.

12. Cosmetic composition for topical application comprising at least one active ingredient according to one of the preceding claims and a physiologically acceptable medium.

13. Cosmetic composition according to the preceding claim, in which the active ingredient represents at least 0.1% by weight of the total weight of the composition.

14. Cosmetic use of an active ingredient according to one of claims 1 to 11 or of a cosmetic composition according to one of claims 12 or 13, for an anti-aging effect.

15. Cosmetic use according to the preceding claim for an anti-wrinkle effect.

16. Cosmetic use according to claim 14 for improving the radiance of the complexion.

17. Cosmetic use according to claim 14 for improving the quality of the dermo-epidermal junction.

18. Cosmetic use according to claim 14 for improving skin homeostasis.